Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 4/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13763312 | 0.97 | DNM1 (0.48) | TSHRDNM1OPRM1LMNATHRB | |
| SCHEMBL13067705 | 0.97 | DNM1 (0.48) | TSHRDNM1OPRM1LMNATHRB | |
| SCHEMBL22625454 | 0.97 | DNM1 (0.48) | TSHRDNM1OPRM1LMNATHRB | |
| SCHEMBL1131040 | 0.97 | TSHR (0.48) | TSHRDNM1OPRM1LMNATHRB | |
| SCHEMBL24044418 | 0.94 | TSHR (0.46) | TSHRDNM1OPRM1LMNATHRB | |
| SCHEMBL13601912 | 0.94 | TSHR (0.46) | TSHRDNM1OPRM1LMNATHRB | |
| SCHEMBL4745188 | 0.94 | TSHR (0.46) | TSHRDNM1OPRM1LMNATHRB | |
| SCHEMBL366647 | 0.94 | TSHR (0.46) | TSHRDNM1OPRM1LMNATHRB | |
| SCHEMBL12844942 | 0.94 | TSHR (0.46) | TSHRDNM1OPRM1LMNATHRB | |
| SCHEMBL985792 | 0.94 | TSHR (0.46) | TSHRDNM1OPRM1LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114478241-A | Preparation method of arylformyl formic ether | 山东京博生物科技有限公司 | 2022-05-13 | — | — | CN | claimed |
| CN-116217590-A | Spiro compound, preparation method and application thereof | 中国科学院上海药物研究所 | 2023-06-06 | — | — | CN | disclosed |
| CN-110845364-B | Preparation method of nitrile compound with formamide as cyanogen source | 湘潭大学 | 2023-02-03 | — | — | CN | disclosed |
| CN-114478241-A | Preparation method of arylformyl formic ether | 山东京博生物科技有限公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-3266783-A1 | DERIVATIVES OF AZA ADAMANTANES AND USES THEREOF | Connexios Life Sciences Pvt. Ltd. (IN) | 2018-01-10 | — | — | EP | disclosed |
| EP-2794607-B1 | DERIVATIVES OF AZA ADAMANTANE AND USES THEREOF | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2017-05-10 | — | — | EP | disclosed |
| EP-2794607-A1 | DERIVATIVES OF AZA ADAMANTANE AND USES THEREOF | Connexios Life Sciences Pvt. Ltd. (IN) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013111150-A1 | DERIVATIVES OF AZA ADAMANTANE AND USES THEREOF | CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) | 2013-08-01 | — | — | WO | disclosed |
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2007062308-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | EGFR, ERBB2, ERBB4 | TSHR 269/4885DNM1 1913/4885OPRM1 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.